Wegovy for PCOS: what the evidence says and what to discuss with your prescriber

Why weight loss matters in PCOS, and where semaglutide fits

PCOS and weight are tightly bound. Insulin resistance, which affects the majority of women with the condition, makes weight harder to lose through diet and exercise alone, and excess weight, in turn, worsens insulin resistance, disrupts ovulation and raises androgen levels. Breaking that cycle is a central goal of most PCOS management plans.

Semaglutide, the active medicine in Wegovy, acts on GLP-1 receptors involved in appetite regulation and slows gastric emptying, which reduces how much you eat. In the STEP 1 trial (published in the New England Journal of Medicine) adults using semaglutide 2.4mg alongside lifestyle changes achieved around 15% average body-weight reduction over 68 weeks. That scale of weight loss, in broader research on PCOS, has been associated with improvements in menstrual regularity, androgen levels and metabolic markers.

The honest qualifier: those STEP 1 participants were not selected for PCOS. Specific evidence on Wegovy in PCOS populations at weight-management doses is still limited. Some smaller studies and early real-world data are encouraging, but the field is moving quickly and a specialist in reproductive endocrinology or your GP is best placed to interpret what the current evidence means for your particular situation. You can read more about how semaglutide relates to PCOS through our overview on semaglutide and PCOS.

Which women with PCOS might be clinically suitable for Wegovy

The licensed eligibility criteria for Wegovy are set by the medicine's UK authorisation, not by a PCOS diagnosis. Adults qualify if they have a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition. PCOS can represent that weight-related condition in some cases, though the prescriber will assess your full medical history rather than the diagnosis alone.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, worth checking if this is relevant to you. A quick way to orient yourself before a consultation: use the NHS BMI calculator to confirm your current BMI, which takes under a minute and gives you a concrete starting point for the conversation with a prescriber.

Beyond BMI, a prescriber will want to know about other conditions you manage, any medicines you take (including oral contraceptives and fertility treatments), and your plans around pregnancy. Women with PCOS who are not actively trying to conceive and who meet the weight criteria are often in scope for an assessment; those who are trying to conceive, pregnant or breastfeeding are not suitable for Wegovy. The prescriber's role is to map all of this before any prescription is issued, and at nume, that review is done by a GPhC-registered Independent Prescriber, not by automated software. Our free consultation is where that process starts.

Pregnancy, fertility and the contraception question

This is the section that matters most for women with PCOS, and it deserves a clear answer. Wegovy is not recommended during pregnancy, breastfeeding or when actively trying to conceive. The NHS and the medicine's prescribing information are unambiguous on this point. If you are using Wegovy and your circumstances change, stop treatment and speak to your GP or specialist promptly, our page on Wegovy and pregnancy covers this in detail.

The fertility dimension of PCOS adds a layer of complexity. Weight loss can, in some women with PCOS, restore more regular ovulation. That is generally a positive development, but it also means that contraception planning becomes active and important during treatment, and if you are wondering whether alcohol fits into your routine on Wegovy, our guide on whether you can drink on Wegovy walks through the practical considerations. For women on oral contraceptives, semaglutide (unlike tirzepatide) does not carry a specific pill-absorption warning, though your prescriber will review your contraception as part of the assessment. NHS England's guidance on weight-management injections covers contraception and related considerations in full.

If conception is a future goal, discuss the recommended washout period with your prescriber before stopping treatment. This is not a decision to make unilaterally. Our page on Wegovy and pregnancy planning sets out the current guidance.

Side effects and ongoing monitoring that PCOS patients should know about

The side-effect profile of Wegovy is GI-led: nausea, vomiting, constipation, diarrhoea and indigestion are the most frequently reported, particularly in the early weeks or following a dose increase. Most women find these settle as the body adjusts. The NHS medicines page for semaglutide lists what to expect and when to seek help.

For women with PCOS managing insulin resistance or type 2 diabetes, blood glucose monitoring during treatment is worth discussing with your GP or specialist, as semaglutide influences blood sugar regulation. Anyone on metformin (a common PCOS medicine) should confirm compatibility with their prescriber.

Wegovy also holds a separate UK authorisation for reducing cardiovascular event risk in eligible adults. Women with PCOS carry a higher baseline cardiovascular risk than the general population, which may make that aspect relevant over time; our page on Wegovy and heart health covers the evidence. If fatty liver disease is part of your picture, Wegovy and liver health has the latest on that authorisation too.

The bottom line on side effects: if something feels wrong, contact a clinician. Severe or persistent stomach pain should be assessed urgently. You can report any suspected side effect (or flag a supplier you are concerned about) through the MHRA Yellow Card scheme.